Postpartum Depression

Program Overview

This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Distinguishing PPD From "Baby Blues"

Postpartum Anxiety

Barriers to Care

Inadequate Treatment of PPD

Impact of PPD on Mother and Child

Screening for PPD

Edinburgh Postnatal Depression Scale

Patient Health Questionnaire-2

Screening for PPD: Recommendations

Risk for PPD: Gene-Environment Interaction

Potential Endocrine Influences on PPD

Treatment of PPD

Emerging Treatments for PPD: Estradiol

Emerging Therapy: Targeting the GABAA Receptor

Phase 3 Study of Brexanolone in Moderate PPD

Phase 3 Study of Brexanolone in Severe PPD

Moderate PPD: Common Presentation

Severe PPD: Common Presentation

Assessing Potential for Harm: Distinguishing PPD From Postpartum Psychosis

Conclusions

Abbreviations

Abbreviations (cont)